Vis enkel innførsel

dc.contributor.authorHovland, Anders
dc.contributor.authorMundal, Liv
dc.contributor.authorVeierød, Marit Bragelien
dc.contributor.authorHolven, Kirsten Bjørklund
dc.contributor.authorBogsrud, Martin Prøven
dc.contributor.authorTell, Grethe Seppola
dc.contributor.authorLeren, Trond Paul
dc.contributor.authorRetterstøl, Kjetil
dc.description.abstractFamilial hypercholesterolemia (FH) is a common, inherited disease characterized by high levels of low-density lipoprotein Cholesterol (LDL-C) from birth. Any diseases associated with increased LDL-C levels including atherosclerotic cardiovascular diseases (ASCVDs) would be expected to be overrepresented among FH patients. There are several clinical scoring systems aiming to diagnose FH, however; most individuals who meet the clinical criteria for a FH diagnosis do not have a mutation causing FH. In this review, we aim to summarize the literature on the risk for the various forms of ASCVD in subjects with a proven FH-mutation (FH+). We searched for studies on FH+ and cardiovascular diseases and also included our and other groups published papers on FH + on a wide range of cardiovascular and other diseases of the heart and vessels. FH + patients are at a markedly increased risk of a broad range of ASCVD. Acute myocardial infarction (AMI) is the most common in absolute numbers, but also aortic valve stenosis is by far associated with the highest excess risk. Per thousand patients, we observed 3.6 incident AMI per year compared to 1.9 incident aortic valve stenosis, however, standardized incidence ratio (SIR) for incident AMI was 2.3 compared to 7.9 for incident aortic valve stenosis. Further, occurrence of ischemic stroke seems not to be associated with increased risk in FH+. Clinicians should be aware of the excess risk of almost all kind of ASCVD in FH+, and the neutral risk of stroke need to be studied further in FH + patients.en_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.titleThe risk of various types of cardiovascular diseases in mutation positive familial hypercholesterolemia; a reviewen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.rights.holderCopyright 2022 The Author(s)en_US
dc.source.journalFrontiers in Geneticsen_US
dc.identifier.citationFrontiers in Genetics. 2022, 13, 1072108.en_US

Tilhørende fil(er)


Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal